JP2020534828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534828A5 JP2020534828A5 JP2020516422A JP2020516422A JP2020534828A5 JP 2020534828 A5 JP2020534828 A5 JP 2020534828A5 JP 2020516422 A JP2020516422 A JP 2020516422A JP 2020516422 A JP2020516422 A JP 2020516422A JP 2020534828 A5 JP2020534828 A5 JP 2020534828A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- ile
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 213
- 108090000765 processed proteins & peptides Proteins 0.000 claims 81
- 229920001184 polypeptide Polymers 0.000 claims 79
- 102000004196 processed proteins & peptides Human genes 0.000 claims 79
- 235000001014 amino acid Nutrition 0.000 claims 51
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 49
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 33
- 108091008874 T cell receptors Proteins 0.000 claims 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000016914 ras Proteins Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000003259 recombinant expression Methods 0.000 claims 6
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 5
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 5
- 108700020796 Oncogene Proteins 0.000 claims 5
- 102000043600 human HRAS Human genes 0.000 claims 5
- 102000049555 human KRAS Human genes 0.000 claims 5
- 102000047526 human NRAS Human genes 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 241000713810 Rat sarcoma virus Species 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 102210029654 HLA-DRB1*07:01 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 150000002333 glycines Chemical group 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560930P | 2017-09-20 | 2017-09-20 | |
| US62/560,930 | 2017-09-20 | ||
| PCT/US2018/051641 WO2019060349A1 (en) | 2017-09-20 | 2018-09-19 | CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534828A JP2020534828A (ja) | 2020-12-03 |
| JP2020534828A5 true JP2020534828A5 (https=) | 2021-11-11 |
| JP7256794B2 JP7256794B2 (ja) | 2023-04-12 |
Family
ID=63963389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516422A Active JP7256794B2 (ja) | 2017-09-20 | 2018-09-19 | 変異型ｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11306132B2 (https=) |
| EP (1) | EP3684799A1 (https=) |
| JP (1) | JP7256794B2 (https=) |
| KR (2) | KR20250037592A (https=) |
| CN (2) | CN120082603A (https=) |
| AR (1) | AR112902A1 (https=) |
| AU (2) | AU2018335274B2 (https=) |
| BR (1) | BR112020005469A2 (https=) |
| CA (1) | CA3076339A1 (https=) |
| CR (1) | CR20240019A (https=) |
| EA (1) | EA202090652A1 (https=) |
| IL (1) | IL273254B2 (https=) |
| MA (1) | MA50180A (https=) |
| MX (2) | MX2020003117A (https=) |
| SG (1) | SG11202002425PA (https=) |
| TW (1) | TWI825029B (https=) |
| WO (1) | WO2019060349A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| US20220291215A1 (en) * | 2019-07-30 | 2022-09-15 | University Health Network | Methods of identifying t cell receptors |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| KR20220143875A (ko) * | 2020-02-14 | 2022-10-25 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체 |
| CA3170658A1 (en) * | 2020-02-19 | 2021-08-26 | Aelin Therapeutics | Molecules targeting mutant ras protein |
| EP4110804A1 (en) * | 2020-02-26 | 2023-01-04 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
| WO2021262829A2 (en) * | 2020-06-24 | 2021-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against cd20 |
| EP4178976A1 (en) * | 2020-07-13 | 2023-05-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| AU2021309958A1 (en) * | 2020-07-16 | 2023-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II-restricted DRB T cell receptors against RAS with G12V mutation |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| TW202229327A (zh) * | 2020-10-02 | 2022-08-01 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| US20240000834A1 (en) * | 2020-11-24 | 2024-01-04 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114835800B (zh) * | 2022-05-27 | 2023-10-13 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| WO2024072954A1 (en) * | 2022-09-29 | 2024-04-04 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine |
| WO2026019786A1 (en) * | 2024-07-16 | 2026-01-22 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting brachyury antigen and methods of use |
| WO2026024602A2 (en) * | 2024-07-22 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors against ras with g12d, g12v, g13d or q61r mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| CN118994363A (zh) * | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| HRP20221183T1 (hr) | 2016-08-02 | 2022-12-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | T-stanični receptori anti-kras-g12d |
-
2018
- 2018-09-19 KR KR1020257006999A patent/KR20250037592A/ko active Pending
- 2018-09-19 CN CN202510245856.3A patent/CN120082603A/zh active Pending
- 2018-09-19 BR BR112020005469-0A patent/BR112020005469A2/pt unknown
- 2018-09-19 MA MA050180A patent/MA50180A/fr unknown
- 2018-09-19 EA EA202090652A patent/EA202090652A1/ru unknown
- 2018-09-19 CA CA3076339A patent/CA3076339A1/en active Pending
- 2018-09-19 SG SG11202002425PA patent/SG11202002425PA/en unknown
- 2018-09-19 JP JP2020516422A patent/JP7256794B2/ja active Active
- 2018-09-19 WO PCT/US2018/051641 patent/WO2019060349A1/en not_active Ceased
- 2018-09-19 US US16/135,231 patent/US11306132B2/en active Active
- 2018-09-19 EP EP18792591.2A patent/EP3684799A1/en active Pending
- 2018-09-19 KR KR1020207011112A patent/KR102777370B1/ko active Active
- 2018-09-19 AU AU2018335274A patent/AU2018335274B2/en active Active
- 2018-09-19 CR CR20240019A patent/CR20240019A/es unknown
- 2018-09-19 CN CN201880060535.4A patent/CN111201237B/zh active Active
- 2018-09-19 IL IL273254A patent/IL273254B2/en unknown
- 2018-09-19 MX MX2020003117A patent/MX2020003117A/es unknown
- 2018-09-20 TW TW107133221A patent/TWI825029B/zh active
- 2018-09-20 AR ARP180102695A patent/AR112902A1/es unknown
-
2020
- 2020-03-19 MX MX2024004610A patent/MX2024004610A/es unknown
-
2022
- 2022-03-11 US US17/692,787 patent/US12304940B2/en active Active
-
2025
- 2025-04-09 AU AU2025202532A patent/AU2025202532A1/en active Pending
- 2025-04-22 US US19/185,924 patent/US20250250318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534828A5 (https=) | ||
| JP2021505136A5 (https=) | ||
| Ho et al. | Bacteriophage λ protein c II binds promoters on the opposite face of the DNA helix from RNA polymerase | |
| IL273254B1 (en) | HLA type II-restricted T cell receptors against RAS | |
| JP2015535816A5 (https=) | ||
| JP2018535647A5 (https=) | ||
| WO2003011895A2 (en) | Compositions and methods for modulation of immune responses | |
| CN113179631A (zh) | 通过临近使能反应疗法开发的共价蛋白质药物 | |
| JP2022523024A5 (https=) | ||
| US20130203163A1 (en) | Promiscuous pap cd4 t cell epitopes | |
| Sauter et al. | A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetes | |
| JP2023534241A5 (https=) | ||
| JP2022535458A (ja) | Ｂ型肝炎ウイルス特異的なｔ細胞応答 | |
| US8658177B2 (en) | Promiscuous HER-2/Neu CD4 T cell epitopes | |
| WO2015072750A1 (ko) | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 | |
| JP2023535366A5 (https=) | ||
| NZ805541A (en) | Hla class i-restricted t cell receptors against mutated ras | |
| EP4670731A1 (en) | HSP70 AND ITS ACTIVE PARTS FOR USE IN THE TREATMENT OF IMMUNOPARALYSIA | |
| KR100455902B1 (ko) | Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드 | |
| WO2026062244A1 (en) | COMPOSITIONS COMPRISING sTIGIT AND PD-1/PD-L1 AXIS INHIBITORS AND USES THEREOF | |
| AU2002324581A1 (en) | Compositions and methods for modulation of immune responses | |
| NZ779633A (en) | T cell receptors recognizing hla-cw8 restricted mutated kras |